02.09.2010 • NewsTotalSanofiGenzyme deal

Total Hopes to Sell Lindsey Refinery by Year-end

French oil company Total has received offers for its UK Lindsey refinery and hopes to sell it by the end of the year, Chief Executive Officer Christophe de Margerie, said on Wednesday.

"We have some offers, we're working on it. We'll talk about it when the moment is right but for the moment the target is that we sell it at the end of the year," de Margerie told journalists on the sidelines of a conference organized by French employers' union Medef.

Referring to the wider market de Margerie said he thought the oil price was "at the right level," while gas prices were low.
"That is a concern for long-term investments but at the same time when you invest today, it is to produce in 8 to 10 years time," he said.

Won't interfere in Sanofi-Genzyme

Total's CEO said he would not comment on the pricing specifics of French pharmaceutical giant Sanofi-Aventis' interest in U.S.-based biotech Genzyme. Total owns a 7.33% stake in Sanofi.

"We are on the board with a relatively small percentage in the share capital. It's up to the management to decide where they want to go and then to ask the board of directors if it is acceptable," de Margerie said.

Genzyme on Monday rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis on Monday, setting the stage for a protracted and potentially hostile takeover battle.

On Tuesday, Genzyme's Chief Executive Henri Termeer said he was willing to sell the company he built up over 25 years, but not for $69 a share.
"I don't think it's good to comment on the price, we will not interfere in the negotiation between two companies," de Margerie said.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.